Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
North America Remote Patient Monitoring Market Size & Share 2026-2035
Report ID: GMI15367
|
Published Date: November 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:
North America Remote Patient Monitoring Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
North America Remote Patient Monitoring Market Size
The North America remote patient monitoring market was valued at USD 14.80 billion in 2025, rising to USD 16.70 billion in 2026, and is projected to expand at a CAGR of 8.6% (2026-2035) to reach USD 35.20 billion by 2035.
North America Remote Patient Monitoring Market Key Takeaways
Market Leader: Abbott Laboratories led with over 13% market share in 2025.
Leading Players: Top 5 players in this market include Abbott Laboratories, Dexcom Inc., Medtronic plc, ResMed Inc., iRhythm Technologies, which collectively held a market share of 47% in 2025.
The North America remote patient monitoring market is shifting from episodic virtual-care deployments toward embedded chronic-care infrastructure. Demand is supported by recurring device replacement, software subscriptions, and clinical-management services, while reimbursement design and care-delivery capacity determine how quickly providers can convert remote data into sustained patient enrollment.
GMI Analyst View
Based on our analysis of historical market trajectories, the North America remote patient monitoring market generated USD 9.00 billion in 2022. We view the intervening expansion as evidence that RPM has moved beyond a temporary access solution: reimbursement-enabled clinical workflows, broader CGM prescribing, and hospital-at-home operating models have established a more durable revenue base. The next phase should reward vendors that can support larger patient panels without increasing clinical-data handling burdens.
North America Remote Patient Monitoring Market Trends, Growth Drivers & GMI Forecast Outlook
Chronic disease management, hospital-at-home delivery, and reimbursable monitoring workflows are moving RPM from isolated programs into enterprise care models. The forecast depends on whether providers can extend that model beyond digitally mature health systems while managing cybersecurity exposure, integration complexity, and uneven residential connectivity.
Key Drivers
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Diabetes creates an unusually durable RPM demand pool because CGM adoption combines a recurring sensor cycle with an ongoing need for clinical interpretation, medication adjustment, and patient engagement. The opportunity extends beyond established treatment populations: 115.2 million U.S. adults had prediabetes in 2023, widening the potential pathway from consumer metabolic tracking to clinically supervised monitoring [1]. This favors suppliers that can connect device data to actionable care-management workflows rather than offering a sensor alone.
Hospital-at-home programs create a distinct institutional purchasing mechanism. Their care models require dependable physiologic surveillance across cardiac, respiratory, and general medical patients, increasing demand for wearable sensing, alert management, and services that can support distributed clinical teams. Reimbursement pathways further reduce the deployment risk for physician groups, allowing RPM capacity to become an operating asset rather than a stand-alone digital-health experiment.
Key Restraints
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
RPM expands the protected-health-information perimeter into patient homes, connected devices, cloud platforms, and clinical dashboards. Providers consequently assess encryption, access controls, auditability, incident response, and vendor accountability before committing to broad deployments. The sector's breach-cost exposure makes security capability a procurement criterion and a margin consideration, especially for smaller practices with limited technology resources.
Connectivity limits create a separate constraint because clinical value depends on dependable transmission rather than device availability alone. The FCC's Rural Health Care Program supports eligible provider facilities, but patient-home connectivity remains a practical limitation for many remote-care models [4]. Meanwhile, mixed device protocols and fragmented data architectures make integration work more expensive and delay deployment, particularly where a health system must combine several monitoring modalities within one clinical workflow.
GMI Analyst View
We believe the forecast's central tension is not whether clinical demand exists, but whether RPM operators can convert that demand into scalable, secure service delivery. Urban health systems with established digital infrastructure and value-based contracting are positioned to expand first. Adoption in smaller, rural, and less-integrated settings will depend on lower implementation friction and clearer economics for managing data at scale.
North America Remote Patient Monitoring Market Segment Analysis
By Product Type
Blood glucose monitoring (CGM) accounted for 37.0% of North America remote patient monitoring market revenue in 2025 and is forecast to grow at a CAGR of 6.8% (2026-2035). Its scale reflects the clinical regularity of diabetes monitoring and the established prescribing, reimbursement, and data-review ecosystem around CGM. Category growth is increasingly shaped by product mix, as broader biosensor access expands reach while placing greater importance on differentiated software, clinician workflows, and patient-retention capabilities.
Cardiac monitoring generated USD 2.96 billion in 2025 and is projected to reach USD 6.33 billion by 2035. Ambulatory ECG monitoring, implantable-device telemetry, and heart-failure surveillance create several recurring service models within this segment. Vendors with installed cardiac-device fleets and clinician alert infrastructure are positioned to benefit from replacement cycles and longitudinal patient management rather than relying solely on new-device placements.
Respiratory monitoring is projected to represent 13.0% of market revenue by 2035 and is expected to expand at a CAGR of 10.4% (2026-2035). Connected sleep therapy, pulmonary disease management, and hospital-at-home protocols broaden the segment's addressable use cases. Demand is supported by the need to verify therapy adherence and identify deterioration outside conventional care settings, which makes interoperable respiratory data and escalation workflows commercially important.
Multiparameter monitoring is projected to reach USD 3.87 billion by 2035 and is expected to grow at a CAGR of 11.0% (2026-2035). The segment is increasingly relevant to higher-acuity home monitoring because it consolidates several physiologic signals into a single care workflow. Its competitive advantage rests on signal quality, alert prioritization, and the ability to limit clinical alarm fatigue while supporting distributed care teams.
Blood pressure monitoring generated USD 1.18 billion in 2025 and is projected to account for 8.0% of revenue by 2035. The category has broad relevance across primary care, cardiovascular follow-up, and chronic-condition management, but its commercial differentiation is shifting from connected hardware toward enrollment tools, adherence support, and clinical reporting. Suppliers that integrate readings into practical care-management programs are better positioned than vendors competing on device connectivity alone.
Sleep monitoring represented 7.0% of revenue in 2025 and is projected to reach USD 2.81 billion by 2035. Sleep-related RPM is supported by the need to manage therapy adherence and assess chronic conditions that affect cardiometabolic outcomes. Its value proposition is strongest where monitoring is linked to a clinical intervention pathway rather than treated as a standalone wellness data stream.
Neurological monitoring is projected to reach USD 2.11 billion by 2035 and is anticipated to expand at a CAGR of 13.1% (2026-2035). Wearables for seizure detection, movement tracking, and rehabilitation adherence are extending monitoring into clinical areas historically dependent on episodic assessment. Commercial progress will depend on demonstrated clinical utility, reimbursement support, and the ability to translate continuous signals into decisions that clinicians can use.
Fetal & neonatal monitoring accounted for 3.0% of revenue in 2025 and is projected to reach USD 1.05 billion by 2035. The segment addresses a specialized care environment in which reliability, clinical oversight, and integration with obstetric or neonatal workflows carry greater importance than broad consumer adoption. Expansion is likely to follow provider confidence in remote-care protocols and payer support for defined high-risk populations.
By Application
Cardiovascular diseases generated USD 4.44 billion in 2025 and are projected to represent 26.0% of market revenue by 2035. The application spans arrhythmia surveillance, heart-failure management, implantable-device telemetry, and hypertension monitoring, providing a broad clinical base for RPM deployment. Its long-term position depends on whether providers can consolidate these use cases into coordinated cardiovascular pathways rather than operate separate monitoring programs.
Diabetes is projected to reach USD 11.26 billion by 2035 and is expected to grow at a CAGR of 9.2% (2026-2035). CGM remains central to this application, but the commercial opportunity increasingly includes connected therapy management, data interpretation, and population-health services. Providers and vendors that can turn high-frequency glucose data into more efficient clinical intervention should capture the greatest value from expanding patient enrollment.
Respiratory diseases represented 13.0% of revenue in 2025 and are projected to generate USD 4.92 billion by 2035. Chronic pulmonary care, sleep-related therapy, and acute respiratory oversight each support the adoption of continuous or near-continuous monitoring. The segment benefits when RPM is integrated with care-transition and hospital-at-home models, where timely escalation can influence utilization and patient outcomes.
Neurological disorders generated USD 1.18 billion in 2025 and are expected to grow at a CAGR of 8.5% (2026-2035). The application's progression depends on moving from data capture to clinically trusted decision support for seizures, movement disorders, and post-stroke recovery. Adoption is likely to remain selective until care teams have clearer pathways for responding to remotely detected changes.
Cancer accounted for 7.0% of revenue in 2025 and is forecast to expand at a CAGR of 10.3% (2026-2035). Oncology RPM can support symptom tracking, treatment surveillance, and more responsive management between visits. The segment's commercial development will be tied to whether cancer centers incorporate monitoring into quality programs and value-based treatment pathways rather than using it as a supplementary digital service.
Infectious diseases represented 4.0% of revenue in 2025 and are projected to reach USD 1.05 billion by 2035. Demand is shifting from emergency-era monitoring programs toward narrower use cases such as adherence support and post-acute surveillance. This favors platforms that can redeploy their capabilities across chronic and specialty-care programs as infectious-disease monitoring becomes less central to RPM portfolios.
Other applications are projected to account for 9.0% of revenue by 2035 and are expected to grow at a CAGR of 10.0% (2026-2035). Post-surgical follow-up, occupational health, and specialty-care coordination extend RPM beyond its principal chronic-disease categories. Their contribution will depend on whether health systems can reuse enterprise monitoring infrastructure across varied workflows without creating separate operational silos.
By End Use
Home-care settings generated USD 9.17 billion in 2025 and are projected to account for 68.0% of revenue by 2035. The North America remote patient monitoring market is increasingly anchored in care delivery at home, where connected devices can replace intermittent in-person measurements with continuous, actionable clinical data. Growth depends on operational models that combine patient onboarding, data triage, and timely intervention without shifting an unmanageable workload to clinical teams.
Long-term care is projected to generate USD 7.04 billion by 2035 and represented 25.0% of revenue in 2025. Skilled nursing and assisted-living providers are adopting monitoring to support chronic-care oversight and reduce avoidable transfers. The segment's value proposition is strongest when monitoring data can be incorporated into facility workflows and linked to accountability for patient outcomes.
Other end-use settings represented 13.0% of revenue in 2025 and are anticipated to expand at a CAGR of 7.8% (2026-2035). Outpatient settings, employer-sponsored programs, and specialty-care coordination create additional channels for RPM deployment. Their relative performance will be shaped by the degree to which monitoring can be tied to a defined clinical or financial owner rather than offered as an unconnected service.
GMI Analyst View
We see the most consequential segment shift as the transition from single-condition monitoring toward platform architectures that can support multiple care pathways through one data and workflow layer. This raises the value of integration, alert intelligence, and clinical-service capability. It also makes breadth of clinical coverage more important as health systems seek to avoid managing separate vendor environments for each condition.
North America Remote Patient Monitoring Market Regional Analysis
U.S. Remote Patient Monitoring Market Analysis
In the North America Remote Patient Monitoring Market, the U.S. generated USD 13.32 billion in 2025 and is projected to represent 89.0% of North America market revenue by 2035. Its scale reflects established reimbursement channels, a deep installed base of connected medical devices, and broad provider familiarity with chronic-care monitoring. Growth remains uneven: integrated delivery networks and digitally mature metropolitan systems can operationalize RPM more readily than community providers facing staffing, connectivity, or implementation constraints.
Canada Remote Patient Monitoring Market Analysis
The Canada remote patient monitoring market is projected to reach USD 3.87 billion by 2035 and is forecast to grow at a CAGR of 9.8% (2026-2035). Provincial coverage decisions and public digital-health infrastructure can create concentrated adoption opportunities when access expands for defined patient populations. At the same time, formal assessment and procurement processes can lengthen commercialization timelines, requiring vendors to build market-access and interoperability capabilities suited to provincial health systems.
GMI Analyst View
We expect the regional opportunity to remain commercially asymmetric. The U.S. rewards execution across decentralized provider, payer, and channel relationships, while Canada requires a more deliberate approach to provincial access and public-system integration. Vendors able to adapt their evidence, contracting, and implementation models to these distinct conditions should be better placed than those applying a uniform North American strategy.
North America Remote Patient Monitoring Market Share & Competitive Landscape
The North America remote patient monitoring market share structure is moderately concentrated: Abbott Laboratories, Dexcom Inc., Medtronic plc, ResMed Inc., and iRhythm Technologies collectively accounted for approximately 47% of 2025 revenue. The remaining market is distributed among specialty-device manufacturers, monitoring-platform providers, clinical-service organizations, and health-system programs. Competition therefore extends beyond hardware performance to clinical integration, reimbursement support, installed-base access, and the ability to manage data across multiple care settings.
Abbott Laboratories held a 13% revenue share in 2025. Its FreeStyle Libre franchise provides a substantial CGM foundation, while connected cardiovascular capabilities extend its relevance across chronic-care pathways. Abbott reported that CardioMEMS-supported care reduced heart-failure hospitalizations by 57% in the cited clinical evidence, reinforcing the strategic importance of clinically actionable monitoring data rather than device connectivity alone [5].
Dexcom Inc. also held a 13% revenue share in 2025. The company's position is tied to the Dexcom G7 ecosystem, clinical data review, and its ability to serve both physician-managed and broader metabolic-monitoring populations. Integration with diabetes-management workflows and connected health platforms gives Dexcom a route to capture recurring value beyond sensor sales.
Medtronic plc accounted for an 11% revenue share in 2025. Its diversified presence across connected glucose management, remote cardiac rhythm monitoring, and implantable-device telemetry provides exposure to several RPM revenue pools. Medtronic's installed cardiac base and CareLink Network create a recurring monitoring relationship that can be less dependent on individual new-device transactions.
Koninklijke Philips N.V. competes through enterprise patient-monitoring infrastructure, connected sleep-therapy management, and platform integration for large health systems. Its ability to aggregate signals from different clinical contexts is relevant where providers seek fewer vendor interfaces and more coordinated workflows.
Boston Scientific is concentrated in cardiac monitoring, including ambulatory ECG and remote management for implanted rhythm devices. Its competitive position depends on combining extended monitoring capability with clinician-facing alerting and electrophysiology workflow support.
GE Healthcare serves institutional RPM requirements through high-acuity patient monitoring, hospital-at-home infrastructure, and enterprise virtual-care capabilities. Its relationships with large health systems can support cross-selling where monitoring must connect with established clinical technology environments.
Johnson & Johnson participates through electrophysiology and post-procedural cardiac-monitoring adjacencies. Its opportunity is linked to the expanding need for surveillance after rhythm-management interventions and the integration of remote data into specialist care pathways.
F. Hoffmann-La Roche Ltd contributes through glucose-monitoring devices and digital diabetes-management capabilities. Its role is differentiated by data aggregation and patient-engagement functions that can complement broader diabetes RPM workflows.
OMRON Healthcare is a significant participant in connected blood-pressure monitoring, serving primary-care and chronic-care programs that require reliable patient-generated measurements. Its commercial relevance increases where providers pair devices with enrollment, reimbursement, and clinical follow-up services.
Baxter International participates through acute-care and transitional-care monitoring capabilities acquired with Hillrom. Its RPM positioning is aligned with workflow coordination across hospital, post-acute, and home-based care settings.
BIOTRONIK SE & Co. KG competes in remote cardiac-device monitoring through its Home Monitoring service and connected implantable-device portfolio. Its established electrophysiology presence supports competition for cardiac programs that require automatic data transmission and responsive clinician review.
Sotera Wireless addresses hospital-at-home and post-acute use cases with continuous vital-sign monitoring. Its positioning centers on supporting earlier recognition of deterioration in patients who require more intensive surveillance than conventional home monitoring.
VitalConnect provides wearable multiparameter monitoring for hospital-at-home, cardiac, and general-care applications. Its ability to combine physiologic sensing with analytics-led alert management is important as clinical teams seek to monitor larger remote panels without proportionately increasing review burden.
Recent Industry Developments
In October 2026, Sutter Health expanded its Sutter Sync RPM program to high-hospitalization-risk heart-failure patients in collaboration with Bodyport. The program had enrolled more than 13,000 patients, and Sutter reported that more than 90% of participants with previously uncontrolled high blood pressure achieved control within six months; the reported outcome should be interpreted as a company-reported program result rather than an independently comparative study [7].
In February 2026, Abbott received FDA approval for the CardioMEMS HERO reader, a next-generation component of its heart-failure monitoring program. Abbott stated that the reader is lighter than its predecessor, supports both Wi-Fi and cellular connectivity, and is designed to shorten the daily reading process, potentially improving data continuity in home-based care [5].
In January 2026, Boston Scientific received FDA 510(k) clearance for the BodyGuardian Remote Monitoring System v3.0, while in June 2026, Dexcom received FDA clearance for the Dexcom G7 and G7 15 Day CGM System. These clearances extend the product-refresh cycle in ambulatory cardiac and diabetes monitoring, two of the market's most established clinical use cases [6].
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →